Highly enantioselective hydrogenation of ethyl 5,5-dimethoxy-3- oxopentanoate and its application for the synthesis of a statin precursor

European Journal of Organic Chemistry

Volumn , Issue 5, 2008, Pages 840-846

  Korostylev, Andrei ^a   Andrushko, Vasyl ^a   Andrushko, Natalia ^a   Tararov, Vitali I ^a   König, Gerd ^b   Börner, Armin ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b ratiopharm GmbH   (Germany)

Author keywords

keto esters; Asymmetric catalysis; Hydrogenation; Rhodium; Rosuvastatin; Ruthenium; Statins; Stereoselectivity

Indexed keywords

EID: 46049114957     PISSN: 1434193X     EISSN: 10990690     Source Type: Journal    
DOI: 10.1002/ejoc.200701059     Document Type: Article

References (44)

1. Comprehensive Asymmetric Catalysis (Eds.: E. N. Jacobsen, A. Pfaltz, H. Yamamoto), vol. I-III, Springer-Verlag, Berlin, 1999;
2. Catalytic Asymmetric Synthesis (Ed.: I. Ojima), Wiley-VCH, New York, 2000.
3. a) J. M. Brown, in Comprehensive Asymmetric Catalysis (Eds.: E. N. Jacobsen, A. Pfaltz, H. Yamamoto), Springer-Verlag, Berlin, 1999, vol. I, pp. 121-182;
4. b) T. Ohkuma, M. Kitamura, R. Noyori, in Catalytic Asymmetric Synthesis (Ed.: I. Ojima), Wiley-VCH, New York, 2000, pp. 1-110.
5. T. Ohkuma, R. Noyori, in Comprehensive Asymmetric Catalysis (Eds.: E. N. Jacobsen, A. Pfaltz, H. Yamamoto), Springer-Verlag, Berlin, 1999, vol. I, pp. 204-210.
6. a) O. Labeeuw, D. Blanc, P. Phansavath, V. Ratovelomanana-Vidal, J.-P. Genêt, Eur. J. Org. Chem. 2004, 2352-2358;
7. b) V. Ratovelomanana-Vidal, C. Girard, R. Touati, J. P. Tranchier, B. Ben Hassine, J.-P. Genêt, Adv. Synth. Catal. 2003, 345, 261-274;
8. c) O. Poupardin, C. Greck, J.-P. Genêt, Tetrahedron Lett. 2000, 41, 8795-8797.
9. a) M. Kitamura, T. Ohkuma, S. Inoue, N. Sayo, H. Kumobayashi, S. Akutagawa, T. Ohta, H. Takaya, R. Noyori, J. Am. Chem. Soc. 1988, 110, 629-631;
10. b) R. Noyori, T. Ohkuma, M. Kitamura, H. Takaya, N. Sayo, H. Kumobayashi, S. Akutagawa, J. Am. Chem. Soc. 1987, 109, 5856-5858;
11. c) R. Noyori, H. Takaya, Acc. Chem. Res. 1990, 23, 345-350.
12. a) Z. Zhang, H. Qian, J. Longmire, X. Zhang, J. Org. Chem. 2000, 65, 6223-6226;
13. b) A. Hu, H. L. Ngo, W. Lin, Angew. Chem. Int. Ed. 2004, 43, 2501-2504;
14. c) Y.-G. Zhou, W. Tang, W.-B. Wang, W. Li, X. Zhang, J. Am. Chem. Soc. 2002, 124, 4952-4953.
15. M. J. Burk, T. G. P. Harper, C. S. Kalberg, J. Am. Chem. Soc. 1995, 117, 4423-4424.
16. T. Yamano, N. Taya, M. Kawada, T. Huang, T. Imamoto, Tetrahedron Lett. 1999, 40, 2577-2580.
17. K. Junge, B. Hagemann, S. Enthaler, G. Oehme, M. Michalik, A. Monsees, T. Riermeier, U. Dingerdissen, M. Beller, Angew. Chem. Int. Ed. 2004, 43, 5066-5069.
18. T. Ireland, K. Tappe, G. Grossheimann, P. Knochel, Chem. Eur. J. 2002, 8, 843-852.
19. P. J. Pye, K. Rossen, R. A. Reamer, R. P. Volante, P. J. Reider, Tetrahedron Lett. 1998, 39, 4441-4444.
20. a) I. Karamé, E. Bellur, S. Rotzoll, P. Langer, C. Fischer, J. Holz, A. Börner, Synth. Commun. 2007, 37, 1067-1076;
21. b) C.-C. Pai, C.-W. Lin, C.-C. Lin, C.-C. Chen, A. S. C. Chan, W. T. Tong, J. Am. Chem. Soc. 2000, 122, 11513-11514;
22. c) J. P. Genêt, C. Pinel, V. Ratovelomanana-Vidal, S. Mallart, X. Pfister, L. Bischoff, M. C. Cano de Andrade, S. Darses, C. Galopin, J. A. Laffitte, Tetrahedron: Asymmetry 1994, 5, 675-690.
23. V. I. Tararov, G. König, A. Börner, Adv. Synth. Catal. 2006, 348, 2633-2644.
24. V. I. Tararov, N. Andrushko, V. Andrushko, G. König, A. Spannenberg, A. Börner, Eur. J. Org. Chem. 2006, 5543-5550.
25. Atorvastatin belongs to the class of statins that are very effective inhibitors of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Therefore statins are the most powerful lipid-lowering agents used for reducing cholesterol levels in people with or at risk of cardiovascular disease: Statins, The HMG CoA Reductase Inhibitors in Perspective (Eds: A. Gaw, C. J. Packard, J. Shepherd), Taylor & Francis, 2003.
26. For the application of statins for treatment of hypercholesterolemia and hyperlipidaemia see: a) Contemporary Drug Synthesis (Eds.: J.-J. Li, D. S. Johnson, D. R. Sliskovic, B. D. Roth), Wiley-Interscience, New York, 2004, pp. 113-123;
27. b) W. Insull Jr, Nat. Clin. Pract. Cardiovasc. Med. 2006, 3, 134-135;
28. c) L. Calza, V. Colangeli, R. Manfredi, G. Legnani, L. Tampellini, D. Pocaterra, F. Chiodo, AIDS 2005, 19, 1103-1105.
29. For a systematic review about application of statins in the treatment of chronic heart failure see: P. van der Harst, A. A. Voors, W. H. van Gilst, M. Böhm, D. J. van Veldhuisen, PLoS Med. 2006, 3, e333; and literature cited therein.
30. T. Konoike, Y. Araki, J. Org. Chem. 1994, 59, 7849-7854.
31. Rosuvastatin was approved as the cholesterol-lowering drug Crestor in August, 2003. More about the application of rosuvastatin see: N. S. Culhane, S. L. Lettieri, J. R. Skae, Pharmacotherapy 2005, 25, 990-1000 and literature cited therein.
32. Rosuvastatin appears to reduce low-density lipoprotein (LDL) cholesterol to a greater degree than rivals in the class without additional adverse effects. Rosuvastatin is approved for the treatment of elevated LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia) and/or triglycerides (hypertriglyceridemia). The main competitor to rosuvastatin is atorvastatin, which is the first totally synthetic HMG-CoA-reductase inhibitor that is marketed as a single enantiomer.
33. O. Poupardin, C. Greck, J.-P. Genêt, Synlett 1998, 1279-1281.
34. M. A. Ciufolini, N. Xi, J. Chem. Soc. Chem. Commun. 1994, 1867-1868.
35. D. W. Brooks, L. D.-L. Lu, S. Masamune, Angew. Chem. Int. Ed. Engl. 1979, 18, 72-74.
36. 2 pressure of 50 bar.
37. J. M. Brown, Angew. Chem. Int. Ed. Engl. 1987, 26, 190-203.
38. G. Beck, H. Jendralla, K. Kesseler, Synthesis 1995, 1014-1018.
39. M. Kitamura, T. Ohkuma, H. Takaya, R. Noyori, Tetrahedron Lett. 1988, 29, 1555-1556.
40. A. Togni, C. Breutel, A. Schnyder, F. Spindler, H. Landert, A. Tijani, J. Am. Chem. Soc. 1994, 116, 4062-4066.
41. G. Franciò, C. G. Arena, F. Faraone, C. Graiff, M. Lanfranchi, A. Tiripicchio, Eur. J. Inorg. Chem. 1999, 8, 1219-1227.
42. Unfortunately, it was not possible to increase the yield of (R)-6 higher than noted above.
43. N. Andrushko, V. Andrushko, G. König, A. Spannenberg, A. Börner, Eur. J. Org. Chem. 2008, 847-853, following article.
44. H. E. Gottlieb, V. Kotlyar, A. Nudelman, J. Org. Chem. 1997, 62, 7512-7515.